Loading...
•
Mar 31, 2020
Ultragenyx Q1 2020 Earnings Report
Ultragenyx reported strong financial results with total revenue of $36.3 million and maintained full year 2020 financial guidance.
Key Takeaways
Ultragenyx reported first quarter 2020 financial results, with total revenue of $36.3 million. The company maintains full year 2020 guidance based on COVID-19 impact to date. The FDA reviews for Crysvita for TIO and UX007 for LC-FAOD are on track to be completed in the coming months.
Total revenue for the first quarter of 2020 was $36.3 million.
Crysvita revenue in Ultragenyx territories was $28.8 million.
The company maintains full year 2020 guidance.
FDA reviews for Crysvita for TIO and UX007 for LC-FAOD are on track.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Revenue by Segment
Crysvita Revenue
CapyFin.comMepsevii Revenue
CapyFin.com Forward Guidance
The company currently maintains the guidance range for 2020 Crysvita revenue in the Ultragenyx territories to be between $125.0 million and $140.0 million, although it continues to monitor the COVID-19 pandemic situation. The company also expects a more than 20 percent reduction in net cash burn in 2020 compared to 2019 due to a combination of financial discipline in spending with flattening operating expense growth, combined with a significant anticipated growth in revenue.
Positive Outlook
- Crysvita revenue guidance maintained between $125.0 million and $140.0 million.
- Expects a more than 20% reduction in net cash burn in 2020 compared to 2019.
- Financial discipline in spending.
- Flattening operating expense growth.
- Significant anticipated growth in revenue.
Challenges Ahead
- Continues to monitor the COVID-19 pandemic situation.
- Potential delays in clinical trials due to COVID-19
- Uncertainties related to insurance coverage and reimbursement approval for the company’s products
- Manufacturing risks
- Smaller than anticipated market opportunities for the company’s products and product candidates
Revenue & Expenses
Visualization of income flow from segment revenue to net income